Celltrion’s Biosimilar Adalimumab shows positive Phase III results in Patients With Rheumatoid Arthritis
Celltrion Healthcare Presents Positive One-Year Data for the First High-Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab, YuflymaTM ...
Read more